iNtRON Biotechnology Inc
Company Profile
Business description
iNtRON Biotechnology Inc is a Korea-based biotechnology firm focused on the research, development, and commercialization of biopharmaceuticals and molecular diagnostics. Its core business includes developing bacteriophage- and endolysin-based therapeutic platforms for infectious diseases, immune disorders, microbiome-related diseases, vaccines, and oncology applications. It also develops and manufactures PCR/qPCR-based molecular diagnostic kits for human and animal infectious diseases, supported by GMP-certified automated production facilities. In addition, the company pursues strategic partnerships and equity investments to expand its biotechnology ecosystem and commercialize technologies derived from its drug development programs.
Contact
137 Sagimakgol-ro
701-704, Jungang Induspia 5
Jungwon-gu
Gyeonggi-do
Seongnam-si
KORT: +82 317395678
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,026.88 | 141.78 | 0.26% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,650.22 | 301.87 | 1.15% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,751.96 | 42.00 | 0.54% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |